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1607-551X/Copyright ª 2014, KaohsiuAbstract The thyrotropin-releasing hormone (TRH) test is useful for differentiating central
and primary hypothyroidism, and is also valuable for diagnosing hypothyroidism. The threshold
of the TRH test is usually set at 10e40 mIU/L. However, some experts are of the opinion that
the TRH test has a limited role in evaluating hypothyroidism because of the clinical application
of the new-generation thyroid-stimulating hormone (TSH) assay. We reviewed a case series to
analyze the clinical use of the TRH test in the re-evaluation of congenital hypothyroidism. In
total, data on 228 children with eutopic thyroid glands and neonatal hyperthyrotropinemia un-
der levothyroxine replacement were collected. Basal TSH levels were measured and the TRH
test was performed at the age of 3 years for re-evaluation of congenital hypothyroidism, and
statistical analysis was performed. All of the patients were followed up to avoid over- or under-
treatment. At the age of 3 years, 31.6% of the patients still had hypothyroidism. There was no
significant difference between basal TSH level and TRH test in the diagnosis of hypothyroidism
(p Z 0.23). The negative predictive value of the basal TSH level was 100%, however, the pos-
itive predictive value was only 43.6%. When the TSH level was near the upper limit of the
normal range (4.5e8.5 mIU/L), the TRH test result had a better correlation with hypothyroid-
ism than the basal TSH level (pZ 0.03). The threshold of the TRH test set at 60 mIU/L had theeclare no conflicts of interest.
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384 L.-M. Chen et al.greatest area under the curve, with a negative predictive value of 95.2% and a positive predic-
tive value of 80.2%. Neonatal hyperthyrotropinemia was a risk factor for hypothyroidism. We
suggest that the TRH test should be administered in children with a basal TSH value near
the upper limit of the normal range, and the threshold of the TRH test should be set at
60 mIU/L.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Newborn screening is now widespread, therefore, an
increasing number of cases of congenital hypothyroidism
(CH) are being reported, and it has become a leading cause
of preventable mental retardation, with an incidence
worldwide of around 1 in 3000e4000 [1], and 1 in 2000 in
Taiwan [2]. Newborn screening is usually completed
24 hours after the newborns start to feed. Newborns are
screened for CH with enzyme immunoassays of dried blood
spots, and those with hyperthyrotropinemia are referred
for further evaluation when they are 1e2 weeks old. After
confirmatory tests, those with hypothyroidism are then
started on levothyroxine replacements (10e15 mg/kg/day)
immediately and receive thyroid scintigraphy or sonography
for evaluation of thyroid development. Children with thy-
roid agenesis or ectopia usually need permanent levothyr-
oxine treatment and are diagnosed as having permanent
CH. Those with eutopic thyroid glands may only have
transient neonatal hyperthyrotropinemia and are re-
evaluated at 3 years of age to decide whether hypothy-
roidism persists [3]. It has been suggested that hypothy-
roidism is an ongoing disease state starting with a positive
thyrotropin-releasing hormone (TRH) test, followed by
TSH elevation, and subsequently to overt hypothyroidism
and thyroid hormone failure [4e6]. Re-evaluation mainly
involves the levels of TSH, triiodothyronine (T3), thyroxine
(T4), and free thyroxine (fT4), and the TRH test is also
included in the re-evaluation of CH [1].
The TRH test is also used to detect subclinical hypo-
thyroidism in patients with goiter or depression or in
women with infertility [7e9]. However, many experts re-
gard that it now has a limited role after the clinical appli-
cation of the new generation of TSH assays [10e12], and
the TRH (protirelin) reagent is even unavailable in the
United States currently [13]. We present a retrospective
case analysis to determine whether the TSH assay alone is
sufficient or whether the TRH test still has a role in the
diagnosis of hypothyroidism.Materials and methods
Patient selection
Term newborns in Southern Taiwan suspected of having CH
after newborn screening were referred to Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan. TSH was
measured with immunoradiometric assay (functional
sensitivity: 0.03 mIU/L, intra-assay variation < 5.7%,inter-assay variation < 5.4%) and T3, T4, and fT4 were
evaluated with radioimmunoassays (functional sensitivity:
T3 10 ng/dL, T4 0.25 mg/dL, and fT4 0.05 ng/dL; intra-
assay variation: T3 < 12%, T4 < 5.6%, and fT4 < 8.15%; and
inter-assay variation: T3 < 10.1%, T4 < 14.3%, and
fT4 < 14.9%). If the patient had hyperthyrotropinemia
(TSH level > 20 mIU/L) and/or hypothyroxinemia (T4
level < 15 mg/dL), CH was diagnosed. According to thyroid
scintigraphy (Tc 99m pertechnetate), we collected 228
cases with eutopic thyroid glands (including normal,
goiter, and hypofunction) and 49 cases with thyroid
agenesis or ectopia between 1989 and 2008. This study
was approved by the Institutional Review Board of Kaoh-
siung Medical University Hospital (Number KMUHIRB-
20130070).
TRH test
The patients with eutopic thyroid glands received TRH tests
once they reached the age of 3 years after stopping levo-
thyroxine for 4 weeks. Thyroid hormones (fT4, T4, and T3,
via the radioimmunoassay method) and TSH levels (immu-
noradiometric assay method) were measured immediately
prior to when intravenous TRH (7 mg/kg) was administered,
and the TSH levels were assessed again 30 minutes, 60 mi-
nutes, and 90 minutes later.
The patients with exaggerated peak TSH values (judged
as > 40 mIU/L in this study) were regarded as being hypo-
thyroiditic and kept receiving treatment and regular follow-
up visits. The other patients were classified as being
euthyroiditic, and levothyroxine treatment was ceased.
Serum thyroid function was assessed at least twice 1 month
later with competitive enzyme-linked immunoassay (detec-
tion limit: TSH: 0.01e100 mIU/L, T4: 0.5e30 mg/dL). If
hyperthyrotropinemia (TSH level > 4.5 mIU/L) in combina-
tion with hypothyroxinemia (T4 < 11 mg/dL) developed, the
patients were also regarded as having permanent CH and
levothyroxine therapy was resumed. After 2 years follow-up,
those who were still receiving levothyroxine were classified
as having permanent CH, and the other patients as having
transient CH.
Statistical analysis
The results were analyzed by t tests and one-way analysis
of variance for comparisons between groups. SPSS statis-
tical software version 17.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical analysis. In one-way analysis of
variance, if the Levene test revealed homogenicity, then
Scheffe’s method was used for post-hoc comparisons.
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ences in homogenicity, then the GameseHowell method
was used for post-hoc comparisons. Continuous variables
were summarized with means and standard deviations.
A p value < 0.05 was considered to be statistically signifi-
cant. Different cut-off points of the TRH test were
compared using analyses of receiver operating character-
istic curves.
Results
Thyroid function in the newborn period
The TSH levels of the initial confirmatory test were signif-
icantly higher in the thyroid agenesis group (nZ 19) than in
the eutopic group (n Z 228; mean  standard deviation,
262.43  200.42 mIU/L vs. 120.55  76.66 mIU/L,
pZ 0.017), and the T3, T4, and fT4 levels were lower in the
thyroid agenesis group (Table 1). However, all of them were
poor predictors for permanent CH (Fig. 1).
Thyroid function in the eutopic thyroid group
The incidence of permanent CH was 31.6%, and there was
no significant difference between the male and female in-
fants (30.7% vs. 33.0%, nZ 228, pZ 0.807; Table 2). None
of the three eutopic thyroid conditions (normal, hypo-
function, and hyperfunction) were correlated to the final
outcome (pZ 0.468). The positive predictive rate (PPV) of
basal TSH (threshold: 4.5 mIU/L) was 43.6%, and the
negative predictive rate (NPV) was 100%. The PPV of peak
TSH (threshold: 40 mIU/L) was 53.3%, and the NPV was
100%.
The distribution of transient hyperthyrotropinemia and
permanent CH according to basal TSH and peak TSH values
is shown in Fig. 2. The receiver operating characteristic
curves for the basal and peak TSH levels of TRH test for the
prediction of permanent CH are shown in Fig. 3A. The areas
under the curve (AUC) of the basal and peak TSH levels was
0.950 versus 0.969, respectively (p Z 0.23). For patients
with a basal TSH level >4.5 mIU/L, the difference in AUC
between the basal and peak TSH levels was significant
(Fig. 3B; 0.917 vs. 0.948, respectively, nZ 165, pZ 0.23).
Focusing on the patients with a basal TSH level between 4.5
mIU/L and 8.5 mIU/L, the difference in AUC between the
basal and peak TSH levels was significant (Fig. 3C; 0.570 vs.
0.909, respectively, n Z 76, p Z 0.03).Table 1 Initial confirmatory test between those with eutopic t
Scan No. TSH (mIU/L)a
Eutopia 228 120.55  76.66 13
Agenesis 19 262.43  200.42 6
Ectopia 30 173.52  134.72 12
TSH Z thyroid-stimulating hormone; T3 Z triiodothyronine; T4 Z th
a eutopia < agenesis (p Z 0.017).
b eutopia > agenesis (p < 0.001).
c eutopia > agenesis (p Z 0.028), ectopia > agenesis (p Z 0.022).
d eutopia > agenesis (p < 0.001).Threshold of the TRH test
The threshold of the TRH test was tested with the method
of approach. A threshold between 50 mIU/L and 70 mIU/L
had a higher AUC (Table 3), and a threshold of 60 mIU/L had
the highest AUC (Table 4). The NPV of peak TSH (threshold:
60 mIU/L) was 95.2% and the PPV 80.2% (Table 2).
Fig. 4 describes the distribution of transient HT and
permanent CH according to basal TSH and peak TSH values
in the patients with eutopic thyroid glands with a basal TSH
level <20 mIU/L and peak TSH <100 mIU/L (n Z 183).Discussion
Children with hyperthyrotropinemia in newborn screening
are at an increased risk for the development of subclinical
hypothyroidism in early childhood, with a reported preva-
lence rate up to 70% [14]. The current study excluded the
patients with thyroid agenesis and ectopia, and around
one-third of those with eutopic thyroid glands needed
lifelong levothyroxine treatment, which is consistent with a
previous report [15].
In most situations, basal TSH level is a simple and ac-
curate index for the diagnosis of primary hypothyroidism.
All children with normal basal TSH values in this study had
normal growth and cognitive function without levothyrox-
ine treatment after the age of 3 years. Clinicians face a
dilemma, however, when the basal TSH level is near the
upper limit of the normal range. Subclinical hypothyroidism
may be difficult to assess because it is usually asymptom-
atic and often fluctuates at the basal TSH level [16,17]. In
the current study, both the basal and peak TSH levels had
an excellent NPV of 100% for hypothyroidism, however the
PPV of basal TSH was only 43.6%, whereas that of the TRH
test was slightly higher at 53.3%. These children were fol-
lowed closely to ensure a normal thyroid function and
prevent over-diagnosis. The linear correlation of basal TSH
and peak TSH was in direct proportion (Fig. 2). There were
two slopes of the correlation between basal and peak TSH,
that is, one below 60 mIU/L of basal TSH level and another
above. It may have been due to dilution of the samples.
They both had a good NPV, therefore, we assumed that if
there was a difference in the prediction rate between basal
and peak TSH level, it would be in the group with the lower
basal TSH values, and we found that the greatest difference
was in the group with a basal TSH level higher but near the
upper limit of the normal range. The patients with a basalhyroid glands, agenesis, and ectopia.
T3 (ng/dL)b T4 (mg/dL)c fT4 (ng/dL)d
0.19  48.21 4.74  3.00 0.61  0.47
0.71  40.54 2.82  2.65 0.27  0.07
4.46  40.45 5.25  3.03 0.59  0.55
yroxine; fT4 Z free thyroxine.
Figure 1. Receiver operating characteristic curve: initial
confirmatory test versus permanent hypothyroidism (nZ 280).
The area-under-the-curve (AUC) of thyroid-stimulating hor-
mone (TSH): 0.60 (95% CI, 0.51 to 0.69, p Z 0.024). AUC of
triiodothyronine (T3): 0.32 (95% CI, 0.24 to 0.41, p < 0.001).
AUC of thyroxine (T4): 0.43 (95% CI, 0.34 to 0.52, p Z 0.120).
AUC of free-T4 (fT4): 0.43 (95% CI, 0.34 to 0.52, p Z 0.122).
Figure 2. Distribution of transient hyperthyrotropinemia
(HT) and permanent congenital hypothyroidism (CH) according
to basal thyroid-stimulating hormone (TSH) and peak TSH of
thyrotropin-releasing hormone (TRH) test in patients with
thyroid eutopia (n Z 228).
386 L.-M. Chen et al.TSH level of 4.5e8.5 mIU/L had the greatest difference in
AUC from peak TSH in the prediction of permanent hypo-
thyroidism. This indicated that if a child had a basal TSH
level higher but near the upper limit of normal range,
further evaluation with the TRH test would help to raise the
PPV.
Previous studies have suggested that peak TSH values
above 10e40 mIU/L in the TRH test are exaggerated [18,19].
However, we suggest that a threshold of 60 mIU/L has the
greatest efficacy, because it raised the PPV from 53.3% to
80.2%, while only slightly decreasing the NPV from 100% to
95.2% compared with a threshold of 40 mIU/L (Fig. 4).Table 2 Incidence of transient HT and permanent CH accordin
Variables No. Tr
Male 137
Female 91
Thyroid scan Normal 163
Hyperfunction 49
Hypofunction 16
Basal TSH 4.5 mIU/L 63
>4.5 mIU/L 165
Peak TSH 40 mIU/L 93
>40 mIU/L 135
60 mIU/L 147
>60 mIU/L 81
Total 228
CH Z congenital hypothyroidism; HT Z hyperthyrotropinemia; TSH ZConsidering their near-normal thyroid function during a
previous follow-up, even with poor therapeutic compli-
ance, six children initially presenting with thyroid agenesis
on scintigraphy also participated in re-evaluation when
3 years of age. All six were found to have functional thyroid
glands when they were 3 years old and successfully dis-
continued therapy. Two of them had no recorded history of
an abnormal birth and the other four were hospitalized
after birth for different conditions including maternal
syphilis, congenital heart disease, ileal atresia, with in-
testinal perforation combined with maternal drug abuse,
and congenital diaphragmatic hernia with pneumothorax.
They were all term neonates, thus, the initial thyroid
isotope uptake may have been impaired via the mechanismg to sex, basal TSH, and peak TSH levels.
ansient HT (%) Permanent CH (%) p
95 (69.3) 42 (30.7) 0.807
61 (67.0) 30 (33.0)
115 (70.6) 48 (29.4) 0.468
30 (61.2) 19 (38.8)
11 (68.8) 5 (31.3)
63 (100) 0 (0) <0.001
93 (56.4) 72 (43.6)
93 (100) 0 (0) <0.001
63 (46.7) 72 (53.3)
140 (95.2) 7 (4.8) <0.001
16 (19.8) 65 (80.2)
156 (68.4) 72 (31.6)
thyroid-stimulating hormone.
Figure 3. (A) Receiver operating characteristic (ROC) curve:
basal thyroid-stimulating hormone (TSH) and peak TSH versus
permanent hypothyroidism for patients with thyroid eutopia (n
Z 228). The area-under-the-curve (AUC) of basal TSH: 0.950
(95% CI: 0.925 to 0.976, p < 0.001). AUC of peak TSH: 0.969
(95% CI: 0.951 to 0.987, p < 0.001). AUC of basal TSH & peak
TSH: t Z 1.44, p Z 0.23. (B) ROC curve: basal TSH and peak
TSH versus permanent hypothyroidism for patients with thyroid
eutopia and basal TSH level >4.5 mIU/L(nZ 165). The AUC of
basal TSH: 0.917 (95% CI: 0.875 to 0.959, p < 0.001). AUC of
peak TSH: 0.948 (95% CI: 0.918 to 0.978, p < 0.001). AUC of
basal TSH & peak TSH: tZ 1.44, pZ 0.23. (C) ROC curve: basal
TSH and peak TSH versus permanent hypothyroidism for pa-
tients with thyroid eutopia and basal TSH level 4.5w8.5 mIU/L
(n Z 51). The AUC of basal TSH: 0.570 (95% CI: 0.28 to 0.86,
p Z 0.590). AUC of peak TSH: 0.909 (95% CI: 0.80 to 1.000,
p Z 0.003). AUC of basal & peak TSH: t Z 4.522, p Z 0.033.
Table 3 AUC of receiver operating characteristic curves:
TRH test peak of 40e80 mIU/L versus permanent hypothy-
roidism for patients with eutopic thyroid glands (n Z 228).
Variables AUC Standard
deviation
p 95% confidence interval
Lower
limit
Upper
limit
Peak 40 0.798 0.028 0.000 0.743 0.853
Peak 50 0.858 0.025 0.000 0.809 0.907
Peak 60 0.900 0.025 0.000 0.852 0.948
Peak 70 0.874 0.030 0.000 0.816 0.932
Peak 80 0.855 0.032 0.000 0.792 0.919
AUC Z area under the curve; TRH Z thyrotropin-releasing
hormone.
Table 4 AUC of receiver operating characteristic curves:
TRH test peak of 55e65 mIU/L versus permanent hypothy-
roidism for patients with eutopic thyroid glands (n Z 228).
Variables AUC Standard
deviation
p 95% confidence interval
Lower
limit
Upper
limit
Peak 55 0.886 0.024 0.000 0.839 0.933
Peak 56 0.889 0.024 0.000 0.842 0.935
Peak 57 0.895 0.024 0.000 0.848 0.942
Peak 58 0.894 0.024 0.000 0.846 0.942
Peak 59 0.894 0.024 0.000 0.846 0.942
Peak 60 0.900 0.025 0.000 0.852 0.948
Peak 61 0.893 0.026 0.000 0.843 0.943
Peak 62 0.893 0.026 0.000 0.843 0.943
Peak 63 0.889 0.026 0.000 0.838 0.941
Peak 64 0.893 0.026 0.000 0.841 0.944
Peak 65 0.886 0.027 0.000 0.833 0.939
AUC Z area under the curve; TRH Z thyrotropin-releasing
hormone.
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Figure 4. Distribution of transient hyperthyrotropinemia
(HT) and permanent congenital hypothyroidism (CH) according
to basal thyroid-stimulating hormone (TSH) and peak TSH in
patients with thyroid eutopia with basal TSH < 20 mIU/L and
peak TSH < 100mIU/L (n Z 183). The higher and lower trans-
verse dashed lines mean peak TSH 60 and 40 mIU/L, respec-
tively; the left and right longitudinal dashed lines mean basal
TSH 4.5 and 8.5 mIU/L, respectively.
388 L.-M. Chen et al.of escape from the WolffeChaikoff effect after exposure to
iodine antiseptics with medical intervention [20]. In addi-
tion, a eutopic thyroid gland is more likely to be detected
by 123I scintigraphy over the Tc99 m used in the current
study [21,22]. This means that for patients with thyroid
agenesis, and especially those with concurrent medical
problems, further confirmation with sonography is advised.
The incidence of thyroid hemiagenesis is estimated to be
approximately 0.05% in normal children, with the majority
being left lobe defects [23]. Three cases of thyroid hem-
iagenesis were included in our study (2 of the left lobe and
1 of the right lobe). There were no significant differences in
the initial confirmatory tests and the TRH tests at 3 years of
age between these six children and those with eutopic
thyroid glands (p Z 0.999, data not shown).
There were some limitations to this retrospective study.
Lacking a double-blind design, those with an exaggerated
TSH response would preferably be regarded as having sub-
clinical hypothyroidism and continue to receive levothyr-
oxine treatment when they presented with equivocal
results during follow-up. Further investigations are still
needed.
In conclusion, neonatal hyperthyrotropinemia is a risk
factor for subclinical hypothyroidism. Of the patients with
eutopic thyroid glands, approximately 30% needed perma-
nent treatment. We suggest that the TRH test should be
administered in children with a basal TSH value near the
upper limit of the normal range to rule out subclinical hy-
pothyroidism. A threshold of the TSH peak of 60 mIU/L has
good efficacy for diagnosis.Acknowledgments
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